Enanta Pharmaceuticals (ENTA) Current Leases (2016 - 2026)

Enanta Pharmaceuticals (ENTA) has 10 years of Current Leases data on file, last reported at $3.8 million in Q1 2026.

• Quarterly Current Leases rose 71.17% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 71.17% YoY) and the FY2025 annual result came in at $3.1 million, up 106.43% from the prior year.
• Current Leases climbed to $3.8 million in Q1 2026, from $3.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $5.4 million in Q2 2023 to a low of $1.0 million in Q4 2024.
• A 5-year average of $3.3 million and a median of $3.1 million in 2025 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases slumped 79.74% — and 2025, when it jumped 226.74%.
• Tracing ENTA's Current Leases over 5 years: stood at $3.5 million in 2022, then surged by 42.46% to $5.0 million in 2023, then tumbled by 79.74% to $1.0 million in 2024, then jumped by 226.74% to $3.3 million in 2025, then increased by 14.36% to $3.8 million in 2026.
• The last three Current Leases figures came in at $3.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.